Clinical application of anagrelide as a selective inhibitor of megakaryocyte system

• Published in: Wiadomości lekarskie (1960) Vol. 58; no. 11-12; p. 665
• Main Authors: Najda, Jacek, Stella-Hołowiecka, Beata
• Format: Journal Article
• Language: Polish
• Published: Poland 2005
• Subjects: Fibrinolytic Agents - pharmacology; Fibrinolytic Agents - therapeutic use; Humans; Quinazolines - pharmacology; Quinazolines - therapeutic use; Thrombocytosis - drug therapy; Thrombopoiesis - drug effects
• ISSN: 0043-5147

Anagrelid is, in our country, comparatively a new compound selectively affecting the megakaryocyte line in bone marrow leading to its reversal inhibition, simultaneously showing some exceptional, interesting pharmacological features. Essential trombocythemia, being a sole indication for the drug administration, is one of the chronic myeloproliferative disorders which exposes individuals to significantly increased risk for thrombohaemorrhagic complications. Regarding the latest literature data, the most present therapeutic modalities in this disease were presented focusing the interest on anagrelid being, in majority of cases, the drug of choice in uncontrolled megakaryocyte proliferation. The drug therapeutic value and characteristics were presented on the background of another compounds regarded as standard therapeutic options for essential thrombocythemia.